Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News   Featured News   ProMIS Highlights Advancements Made in 2018

ProMIS Highlights Advancements Made in 2018

Stockhouse Editorial
0 Comments| November 20, 2018
{{labelSign}}  Favorites
{{errorMessage}}
Biotech Company ProMIS Neurosciences Inc. (TSX:PMN, OTCQB:ARFXF, Forum) on Tuesday released its year-to-date overview for 2018 and outlook on priorities for advancing its programs.

To read the highlights in full, click here.

ProMIS recently released it’s Q3 2018 results where the Company received proceeds of $1,797,640 related to the exercise of common stock warrants and stock options.


FULL DISCLOSURE: ProMIS Neurosciences Inc.is a paid client of Stockhouse Publishing.

{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today